These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 2049113)

  • 1. Stimulatory effect of romurtide on hematopoiesis in monkeys.
    Nakajima R; Yshida Y; Akahane K; Sekiguchi M; Osada Y
    Arzneimittelforschung; 1991 Jan; 41(1):60-5. PubMed ID: 2049113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Production of interleukin-6 from macrophages by MDP-Lys (L 18), romurtide.
    Shimoda K; Okamura S; Harada N; Omori F; Niho Y
    Res Commun Chem Pathol Pharmacol; 1990 Dec; 70(3):289-96. PubMed ID: 2093210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of colony-stimulating factor and stimulation of stem cell proliferation by injection of muroctasin.
    Yamaguchi F; Akasaki M; Tsukada W
    Arzneimittelforschung; 1988 Jul; 38(7A):980-3. PubMed ID: 3263869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Muroctasin, a muramyl dipeptide derivative].
    Sosnowska D; Dzierzbicka K; Myśliwski A; Kołodziejczyk AM
    Postepy Hig Med Dosw; 1992; 46(5):521-30. PubMed ID: 1298958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stimulation of macrophages by muroctasin to produce colony-stimulating factors.
    Akahane K; Yamaguchi F; Kita Y; Une T; Osada Y
    Arzneimittelforschung; 1990 Feb; 40(2 Pt 1):179-83. PubMed ID: 1692219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of immune responses by muroctasin.
    Akasaki M
    Arzneimittelforschung; 1988 Jul; 38(7A):976-7. PubMed ID: 3056427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differences in interleukin 1 (IL-1), IL-6, tumor necrosis factor and IL-1 receptor antagonist production by human monocytes stimulated with muramyl dipeptide (MDP) and its stearoyl derivative, romurtide.
    Suzuki K; Torii K; Hida S; Hayashi H; Hiyama Y; Oomoto Y; Takii T; Chiba T; Onozaki K
    Immunopharmacology; 1994; 28(1):31-8. PubMed ID: 7928300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Production of colony-stimulating factor from macrophages by muroctasin.
    Yamaguchi F; Akahane K; Takashi T; Tsukada W
    Arzneimittelforschung; 1988 Jul; 38(7A):983-6. PubMed ID: 3263870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Romurtide, a synthetic muramyl dipeptide derivative, promotes megakaryocytopoiesis through stimulation of cytokine production in nonhuman primates with myelosuppression.
    Namba K; Yamamura E; Nitanai H; Otani T; Azuma I
    Vaccine; 1997 Mar; 15(4):405-13. PubMed ID: 9141212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beneficial effect of muroctasin on experimental leukopenia induced by cyclophosphamide or irradiation in mice.
    Nakajima R; Ishida Y; Yamaguchi F; Otani T; Ono Y; Nomura M; Une T; Osada Y
    Arzneimittelforschung; 1988 Jul; 38(7A):986-92. PubMed ID: 3263871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hematological response to the new synthetic muramyl dipeptide derivative muroctasin after chemotherapy in patients with malignant lymphoma. A randomized crossover trial.
    Hiraoka A; Masaoka T; Satoh T; Ota K; Oyama A; Horiuchi A; Hasegawa H; Nagai K; Kosaki M; Kanemaru A
    Arzneimittelforschung; 1988 Oct; 38(10):1499-501. PubMed ID: 3058133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Local tolerance of muroctasin injection in rabbits.
    Nakashima K; Jindo T; Nomura M
    Arzneimittelforschung; 1988 Jul; 38(7A):1038-9. PubMed ID: 3190798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutagenicity studies of muroctasin.
    Shimada H; Hattori C; Sato T
    Arzneimittelforschung; 1988 Jul; 38(7A):1031-3. PubMed ID: 3056424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic generation of tumoricidal macrophages by muroctasin and interferon-gamma.
    Nagao S; Sato K; Osada Y
    Arzneimittelforschung; 1988 Jul; 38(7A):999-1002. PubMed ID: 3142490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study and clinical pharmacological study of muroctasin.
    Ichihara N; Kanazawa R; Sasaki S; Ono K; Otani T; Yamaguchi F; Une T
    Arzneimittelforschung; 1988 Jul; 38(7A):1043-69. PubMed ID: 3263868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic disposition of 14C-muroctasin in laboratory animals.
    Ono K; Masayasu H; Hashimoto F; Yamada M; Takegoshi T
    Arzneimittelforschung; 1988 Jul; 38(7A):1009-14. PubMed ID: 3190792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Restorative effect of muroctasin on leukopenia caused by anticancer chemotherapy in lung cancer. Comparative study by envelope method.
    Fukuoka M; Takada M; Takifuji N; Sakai N; Ryu S; Masuda N; Matsui K; Negoro S; Kusunoki Y; Tubura E
    Arzneimittelforschung; 1989 Jan; 39(1):90-3. PubMed ID: 2719748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Restorative activity of muroctasin on leukopenia associated with anticancer treatment.
    Tsubura E; Nomura T; Niitani H; Osamura S; Okawa T; Tanaka M; Ota K; Nishikawa H; Masaoka T; Fukuoka M
    Arzneimittelforschung; 1988 Jul; 38(7A):1070-4. PubMed ID: 3190800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Romurtide, a synthetic muramyl dipeptide derivative, accelerates peripheral platelet recovery in nonhuman primate chemotherapy model.
    Namba K; Nitanai H; Otani T; Azuma I
    Vaccine; 1996 Oct; 14(14):1322-6. PubMed ID: 9004440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Augmentation of immune defense mechanisms of the lung by romurtide].
    Hasegawa J; Satoh A; Yagi K; Chida K
    Nihon Kyobu Shikkan Gakkai Zasshi; 1995 Jun; 33(6):605-11. PubMed ID: 7666614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.